

Case Report

Enhancing Cord Lesions with Nitrous-Oxide Toxicity

Rishi Sharma^{1*} and Eric J. Sorenson²¹College of Biological Sciences, University of MN, USA²Department of Neurology, Mayo Clinic, Rochester, MN, USA

*Address for Correspondence: Rishi Sharma, College of Biological Sciences, University of MN, USA,

E-mail: sharm415@umn.edu

Received: 16 December 2018; Accepted: 17 January 2019; Published: 19 January 2019

Citation of this article: Sharma, R., Sorenson, EJ. (2019) Enhancing Cord Lesions with Nitrous-Oxide Toxicity. Arch Clin Case Rep, 2(1): 001-002.

Copyright: © 2019 Sharma R, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 21-year-old man presented to our institution with 6-months of ascending lower-limb numbness which progressed over the initial 6 weeks and has remained static since. He sought medical attention at his local medical center 2 months following symptom onset. A cervical spine MRI revealed a longitudinal intramedullary cervical cord lesion with increased T2-signal and discontinuous dorsal enhancement following gadolinium administration (Figure A1-A3). Concerns regarding an inflammatory myelopathy prompted his treating physician to obtain a brain MRI with contrast and a spinal fluid study, both of which were unremarkable. Other serological testing from his home institution was reportedly negative. The lesion on the cervical MRI had an expansile, mass-like appearance (Figure A1,A3) and further diagnostic investigation was pursued with a spinal cord biopsy which showed marked macrophage infiltration with a few CD3 positive T-cells but no diagnostic features. Following the cord biopsy he developed transient erectile dysfunction. He was felt to have a spinal cord tumor with a non-diagnostic biopsy and referred to our medical center for further investigation.

A follow-up cervical spine MRI done at our institution, 6 months after the onset of his symptoms, showed a reduction in the intramedullary T2-hyperintensity and resolution of the contrast enhancement (Figure B1-B3). His exam at the time of our evaluation demonstrated mild toe extensor weakness, decreased vibration and position sense in the toes, a positive Romberg, and absent reflexes. It was discovered that his roommate had similar symptoms 6 months previously and that both he and the patient had been abusing nitrous oxide in the form of “whippets” with over 200 “hits” a day. At the time of our evaluation his serum vitamin B₁₂ was 186 ng/l (normal: 180-914) and serum methyl malonic acid was 0.37 nmol/l (normal: <0.40 nmol/l). Serum intrinsic factor and neuromyelitis optica antibodies were negative. His serum copper was normal.

Enhancing cord lesions are typically seen in inflammatory, infectious, neoplastic, and vascular disorders. Enhancement in B₁₂-deficiency-related myelopathy is very rare [1]. This case illustrates that enhancing lesions can be seen in toxic myelopathies like those due to nitrous-oxide toxicity. The presence of enhancement therefore does not exclude toxic or metabolic etiologies.




Figure 1: Sagittal (A1, A2, B1, B2) and axial (A3, B3) cervical cord MRIs showing a T2-hyperintensity from C1-5 (A1, A3) which shows multifocal enhancement (A2) 2 months after the onset of his symptoms. Imaging done 4 months later at our institution shows a reduction in the T2-hyperintensity (B1, B3) and resolution the enhancement (B2). Also noted are post-operative changes related to the cord biopsy (dotted arrow).

Nitrous-oxide oxidizes the cobalt core of cobalamin (vitamin B₁₂) and renders it inactive by converting the functional reduced form to the inactive, oxidized form [2]. Nitrous oxide toxicity can therefore cause a myelopathy which is similar to that seen with vitamin B₁₂ deficiency [3]. Individuals with subclinical B₁₂ deficiency may be prone to develop deficits after more limited exposure. Neurological symptoms seen following nitrous oxide anesthesia has been referred to as “anesthesia paresthetica” [4].

Disclosure: Rishi Sharma participated in this write up while doing a summer internship in the Department of Neurology, Mayo Clinic, Rochester, MN as part of their UREP (Undergraduate Research Education Program).

References

1. Kuker, W., Hesselmann, V., Thron, A., de Simone, A. (1997) MRI demonstration of reversible impairment of the blood-CNS barrier function in subacute combined degeneration of the spinal cord. *J Neurol Neurosurg Psychiatry*, 62(3): 298–299.
2. Guttormsen, AB, Refsum, H., Ueland, PM. (1994) The interaction between nitrous oxide and cobalamin. Biochemical effects and clinical consequences. *Acta Anaesthesiol Scand*, 38: 753-756.
3. Singer, MA., Lazaridis, C., Nations, SP., Wolfe, GI. (2008) Reversible nitrous oxide-induced myeloneuropathy with pernicious anemia: case report and literature review. *Muscle Nerve*, 37: 125-129.
4. Kinsella, LJ., Green, R. (1995) ‘Anesthesia paresthetica’: nitrous oxide-induced cobalamin deficiency. *Neurology*, 45: 1608-1610.